Table 3.
The impact of different antiviral treatment courses and immune status on in-hospital mortality in CMV GI diseases.
| Immunocompetent (n = 180) | Immunocompromised (n = 176) | |||||
|---|---|---|---|---|---|---|
| Survival | Death | p-Value | Survival | Death | p-Value | |
| Any treatment (IV or PO) | 81 (53.3%) | 18 (64.3%) | 0.282 | 83 (63.8%) | 30 (65.2%) | 0.868 |
| No treatment (IV or PO) | 71 (46.7%) | 10 (35.7%) | 47 (36.2%) | 16 (34.8%) | ||
| IV + PO (Combo) (+) | 25 (16.4%) | 0 (0%) | 0.016 * | 28 (21.5%) | 3 (6.5%) | 0.022 * |
| IV + PO (Combo) (−) | 127 (83.6%) | 28 (100%) | 102 (78.5%) | 43 (93.5%) | ||
| IV (exclusive) (+) | 24 (15.8%) | 14 (50%) | <0.001 * | 26 (20%) | 21 (45.7%) | 0.001 * |
| IV (exclusive) (−) | 128 (84.2%) | 14 (50%) | 104 (80%) | 25 (54.3%) | ||
| PO (exclusive) (+) | 31 (20.4%) | 4 (14.3%) | 0.453 | 28 (21.5%) | 6 (13%) | 0.21 |
| PO (exclusive) (−) | 121 (79.6%) | 24 (85.7%) | 102 (78.5%) | 40 (87%) | ||
Abbreviations: CMV, cytomegalovirus; GI, gastrointestinal; IV, intravenous; PO, oral; * p ≦ 0.05, calculated by Chi-square or Fisher’s exact test on categorical data.